ALECR.PA Eurofins-Cerep SA

Healthcare Life Sciences Tools & Services Euronext Paris
18,400 EUR
Close of Nov 8, 2026
15,000 18,600
Market cap
EUR 92.8M
P/E
11.9x
P/B
1.14x
ROE
6.3%
Dividend yield
-
Fundamental score
3.3/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ALECR.PA undervalued?

Graham number
Price18,400
Graham value23,630
Discount22.1%

ALECR.PA trades 22.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eurofins-Cerep SA fundamental analysis

8 of 11 checks passed

ROE 2/2

ROE surpassing expectations (22.53%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

ROA 2/2

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

PBV 1/2

The stock's PBV ratio (2.22x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

DER 2/2

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 1/2

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

Net Profit Growth 2/2

This company has consistently achieved strong net profit growth over the past five years, demonstrating a solid financial performance and making it an appealing investment option.

Assets Growth 2/2

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

Graham Number 0/1

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Buffet Intrinsic Value 1/1

Based on Warren Buffett's formula, the company's stock appears undervalued (134.622), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Eurofins-Cerep SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eurofins-Cerep SA

Eurofins-Cerep SA provides various drug discovery services to pharmaceutical, biopharmaceutical, and biotechnology companies France and internationally. The company also provides research services, including compound management, and high-throughout screening and profiling. The company was formerly known as Cerep SA and changed its name to Eurofins-Cerep SA in June 2014. Eurofins-Cerep SA was founded in 1989 and is based in Celle-Lévescault, France. Eurofins-Cerep SA is a sub…

Full company profile